Dai Q, et al. - Searching PubMed, Embase, and Cochrane Library databases, researchers identified 6 relevant studies for this single-arm meta-analysis examining the clinical efficacy and safety of leflunomide for treating psoriatic arthritis (PsA). Following leflunomide treatment, a reduction of ≥50% was noted in 48% of the patients based on Psoriasis Area and Severity Index (PASI) scores; 25% of the patients displayed PASI 75 improvement; a Psoriatic Arthritis Response Criteria response was achieved by 77% of the patients; 38% of the patients experienced adverse events. Findings thereby support the efficacy and good tolerability of leflunomide treatment for PsA, and that it would be a safe and convenient option.